Departments of1Neurological Surgery and.
2Center for Biomedical Image Computing and Analytics and.
Neurosurg Focus. 2023 Jun;54(6):E17. doi: 10.3171/2023.3.FOCUS2337.
The clinical behavior of meningiomas is not entirely captured by its designated WHO grade, therefore other factors must be elucidated that portend increased tumor aggressiveness and associated risk of recurrence. In this study, the authors identify multiparametric MRI radiomic signatures of meningiomas using Ki-67 as a prognostic marker of clinical outcomes independent of WHO grade.
A retrospective analysis was conducted of all resected meningiomas between 2012 and 2018. Preoperative MR images were used for high-throughput radiomic feature extraction and subsequently used to develop a machine learning algorithm to stratify meningiomas based on Ki-67 indices < 5% and ≥ 5%, independent of WHO grade. Progression-free survival (PFS) was assessed based on machine learning prediction of Ki-67 strata and compared with outcomes based on histopathological Ki-67.
Three hundred forty-three meningiomas were included: 291 with WHO grade I, 43 with grade II, and 9 with grade III. The overall rate of recurrence was 19.8% (15.1% in grade I, 44.2% in grade II, and 77.8% in grade III) over a median follow-up of 28.5 months. Grade II and III tumors had higher Ki-67 indices than grade I tumors, albeit tumor and peritumoral edema volumes had considerable variation independent of meningioma WHO grade. Forty-six high-performing radiomic features (1 morphological, 7 intensity-based, and 38 textural) were identified and used to build a support vector machine model to stratify tumors based on a Ki-67 cutoff of 5%, with resultant areas under the curve of 0.83 (95% CI 0.78-0.89) and 0.84 (95% CI 0.75-0.94) achieved for the discovery (n = 257) and validation (n = 86) data sets, respectively. Comparison of histopathological Ki-67 versus machine learning-predicted Ki-67 showed excellent performance (overall accuracy > 80%), with classification of grade I meningiomas exhibiting the greatest accuracy. Prediction of Ki-67 by machine learning classifier revealed shorter PFS for meningiomas with Ki-67 indices ≥ 5% compared with tumors with Ki-67 < 5% (p < 0.0001, log-rank test), which corroborates divergent patient outcomes observed using histopathological Ki-67.
The Ki-67 proliferation index may serve as a surrogate marker of increased meningioma aggressiveness independent of WHO grade. Machine learning using radiomic feature analysis may be used for the preoperative prediction of meningioma Ki-67, which provides enhanced analytical insights to help improve diagnostic classification and guide patient-specific treatment strategies.
脑膜瘤的临床行为并不能完全被其指定的世界卫生组织(WHO)分级所捕捉,因此必须阐明其他预示肿瘤侵袭性增加和复发风险增加的因素。在这项研究中,作者使用 Ki-67 作为临床结果的预后标志物,确定了脑膜瘤的多参数 MRI 放射组学特征,与 WHO 分级无关。
对 2012 年至 2018 年间所有切除的脑膜瘤进行了回顾性分析。使用术前磁共振成像(MRI)进行高通量放射组学特征提取,随后用于开发机器学习算法,根据 Ki-67 指数<5%和≥5%对脑膜瘤进行分层,与 WHO 分级无关。基于机器学习对 Ki-67 分层的预测,评估无进展生存期(PFS),并与基于组织病理学 Ki-67 的结果进行比较。
共纳入 343 例脑膜瘤:291 例为 I 级,43 例为 II 级,9 例为 III 级。中位随访 28.5 个月时,总体复发率为 19.8%(I 级为 15.1%,II 级为 44.2%,III 级为 77.8%)。尽管肿瘤和瘤周水肿体积与脑膜瘤的 WHO 分级无关,但 II 级和 III 级肿瘤的 Ki-67 指数高于 I 级肿瘤。确定了 46 种表现良好的放射组学特征(1 种形态学、7 种基于强度和 38 种纹理),并使用支持向量机模型根据 Ki-67 截断值 5%对肿瘤进行分层,在发现(n=257)和验证(n=86)数据集上,曲线下面积分别为 0.83(95%置信区间 0.78-0.89)和 0.84(95%置信区间 0.75-0.94)。组织病理学 Ki-67 与机器学习预测的 Ki-67 比较显示出优异的性能(总体准确率>80%),其中 I 级脑膜瘤的分类准确率最高。机器学习分类器预测 Ki-67 指数≥5%的脑膜瘤比 Ki-67<5%的肿瘤具有更短的 PFS(p<0.0001,对数秩检验),这与使用组织病理学 Ki-67 观察到的不同患者结局相符。
Ki-67 增殖指数可作为脑膜瘤侵袭性增加的替代标志物,与 WHO 分级无关。放射组学特征分析的机器学习可用于脑膜瘤 Ki-67 的术前预测,这为帮助改善诊断分类和指导患者特异性治疗策略提供了增强的分析见解。